Boston biotech Entrada launches with $59M to tackle deadly disease
December 18, 2018 at 08:00 AM EST
Entrada Therapeutics is launching with a $59M VC round, using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in a cell's mitochondrion.